Indeed, 90-day administration of atorvastatin combined with ezetimibe (40 + 10 mg/day) was associated with a significant reduction in serum levels of ICAM-1 and hsCRP in patients with hypercholesterolemia, but no such effect was observed for ezetimibe monotherapy (10 mg/day) [32]. The gene discussed is ICAM1; the disease is familial hypercholesterolemia.